Obesity Drug Demand Outstrips Supply

Ozempic and Mounjaro makers Novo Nordisk and Eli Lilly are working to boost manufacturing of their diabetes and obesity medications

Related Keywords

Denmark ,Novo Nordisk ,Eli Lilly ,Drug Administration ,Wsjfinance ,Wsjfinance Markets ,Pharmaceuticals ,Healthcare Life Sciences ,Specialized Drugs Medications ,Hormone Products ,Diabetes Drugs ,Regulation Government Policy ,New Products Services ,Capacity Facilities ,Product Service Approvals ,Corporate Industrial News ,Products Services ,Political General News ,Society Community ,Diabetes ,Health ,Medical Conditions ,Obesity ,Social Issues ,Content Types ,Factiva Filters ,C Ampe Industry News Filter ,Synd ,Wsj Pro Com ,Novob Ko ,Dk Novo B ,Rally ,Evan Seigerman ,Doug Langa ,Regulation ,Government Policy ,New Products ,Services ,Capacity ,Facilities ,Product ,Service Approvals ,Corporate ,Industrial News ,Products ,Political ,General News ,Society ,Community ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,